Helix BioPharma Corp. Reports Narrowing Q3 Losses and Increased Cash Reserves
Helix BioPharma Corp. has released its third-quarter financial results, highlighting a significant narrowing of its earnings per share (EPS) loss. The company reported an EPS loss of C$0.04, representing a 55.6% year-over-year improvement in bottom-line performance. In addition to improved earnings metrics, the company demonstrated a substantial increase in liquidity. As of July 31, 2026, cash reserves reached C$804K, a significant rise from the C$65K reported during the same period the previous year.